-
Uncategorized4 days ago
Design and evolution of the tetracycline repressor into sulfonylurea herbicide-responsive gene switches for field crops
Post Content
-
Uncategorized4 days ago
Single-cell spatial pharmacobiology for imaging antibody-based therapies in solid tumors
Nature Biotechnology, Published online: 08 June 2026; doi:10.1038/s41587-026-03171-8 We have developed single-cell spatial pharmacobiology (SSP), which combines in situ imaging of a systemically infused fluorescent therapeutic...
-
Uncategorized4 days ago
StockWatch: Abivax Survives a Roller Coaster Week
More acutely than most companies, Abivax (Euronext Paris and Nasdaq: ABVX) felt firsthand the ups and downs of the proverbial stock market roller coaster this past...
-
Uncategorized4 days agoSTAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
You’re reading the web edition of STAT’s ADA in 30 Seconds newsletter, from the American Diabetes Association’s annual conference. Welcome to the third and final edition...
-
Uncategorized4 days agoSTAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
New data on Boehringer Ingelheim’s obesity candidate suggest the drug may be helpful in cutting liver fat, but it’s not clear how competitive the treatment would...
-
Uncategorized4 days ago
ADA: Lilly’s weight loss mastery shows benefits in menopause, sleep apnea, more
Eli Lilly sauntered into the American Diabetes Association meeting with a commanding lead in the metabolic space and put down more evidence for its pipeline, including...
-
Uncategorized5 days agoSTAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
You’re reading the web edition of STAT’s ADA in 30 Seconds newsletter, from the American Diabetes Association’s annual conference. Sign up here Welcome back! The American Diabetes...
-
Uncategorized5 days agoSTAT+: Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly has already established that its next-generation obesity drug can lead to highly rapid weight loss. Researchers disclosed new data Saturday that provide more details...
-
Uncategorized5 days ago
ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes
Even as Zepbound fires on all cylinders and Foundayo gets off to the races in the oral market, Eli Lilly is keenly aware that the one-size-fits-all...
-
Uncategorized5 days agoSTAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
Detailed data from a mid-stage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly. But it’s not...
An obesity drug deep-dive, and peptides move mainstream
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
